Loading patent…
AssigneesOb Med, Snu R&Db Foundation
InventorsBo Hyun Yoon, Joong Shin Park, Jong Kwan Jun, Chan Wook Park
Estimating the term…
Provided is a method for noninvasive prediction or diagnosis of inflammation and/or infection in amniotic fluid leaked through the cervix into the vagina to predict the concentration of inflammatory markers in the amniotic fluid inside uterus by measuring the concentration of inflammatory markers (various cytokines). Further provided is a method for prediction or diagnosis of inflammation and/or infection in amniotic fluid by measuring the concentration of markers (IL-6, IL-1β IL-8, MCP-1, GRO-α) in the amniotic fluid leaked through the cervix into the vagina in patients with premature rupture of membranes. The method can be performed more stably on pregnant women, as compared to the conventional method for prediction or diagnosis of inflammation and/or infection using invasively collected amniotic fluid.
A method for prediction or diagnosis of intra-amniotic inflammation or infection in a pregnant female subject comprising:
The method as set forth in claim 2, wherein the amniotic fluid collecting apparatus is selected from the group consisting of a syringe, pipette, spoon, cotton swab, swab, Nelaton's catheter, amniotic fluid collecting apparatus disclosed in claim 1 or claim 5 of Korean Patent No. 10-0789849, and amniotic fluid collecting apparatus illustrated in FIG. 2 of Korean Patent Application No. 2010-0031404.
A kit for prediction or diagnosis of inflammation or infection in amniotic fluid leaked through the cervix into the vagina, the kit comprising an antibody that specifically binds to a cytokine selected from the group of inflammatory markers consisting of IL-6, IL-1β, IL-8, MCP-1 and GRO-α, wherein a high risk of inflammation or infection is determined using the kit if the concentration of the cytokine bound to the antibody is as follows:
A biochip for prediction or diagnosis of inflammation or infection in amniotic fluid leaked through the cervix into the vagina, the biochip comprising a solid substrate on which biomolecules are integrated, the biomolecules being selected from the group consisting of a low molecular weight compound, a ligand, an aptamer, a peptide, a polypeptide, a specific binding protein, a high molecular weight compound, and an antibody which binds specifically to a cytokine selected from the group of inflammatory markers consisting of IL-6, IL-1β, IL-8, MCP-1, and GRO-α, wherein a high risk of inflammation or infection is determined using the biochip if the concentration of the cytokine bound to the biomolecules is as follows:
-13. (canceled)
Dependencies are inferred from the claim text.